These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 4692859)
1. Repetitive administration of BCG in prevention and treatment of spontaneous leukemia of AKR mice. Ungaro PC; Drake WP; Mardiney MR J Natl Cancer Inst; 1973 Jan; 50(1):125-8. PubMed ID: 4692859 [No Abstract] [Full Text] [Related]
2. Immunoprophylaxis and treatment of leukemia in AKR mice: repetitive use of BCG. Mardiney MR; Ungaro PC; Drake WP Natl Cancer Inst Monogr; 1973 Dec; 39():89-90. PubMed ID: 4595329 [No Abstract] [Full Text] [Related]
3. Discussion paper: effect of hemolytic streptococci on lymphocytic leukemia in AKR mice. Havas HF Ann N Y Acad Sci; 1976; 277(00):299-301. PubMed ID: 1069550 [No Abstract] [Full Text] [Related]
4. Active immunotherapy of AkR mice spontaneous leukemia. Mathé G; Halle-Pannenko O; Bourut C Rev Eur Etud Clin Biol; 1972 Dec; 17(10):997-1000. PubMed ID: 4660002 [No Abstract] [Full Text] [Related]
5. Prophylactic therapy of spontaneous leukemia in AKR mice by polyadenylic-polyuridylic acid. Drake WP; Cimino EF; Mardiney MR; Sutherland JC J Natl Cancer Inst; 1974 Mar; 52(3):941-4. PubMed ID: 4596992 [No Abstract] [Full Text] [Related]
6. Immunoadjuvant treatment of primary grafted and spontaneous AKR-leukemia. I. Treatment efficiency correlated to autoimmune reactivity. Olsson L; Ebbesen P J Immunol; 1979 Mar; 122(3):772-80. PubMed ID: 376705 [TBL] [Abstract][Full Text] [Related]
7. BCG in cancer immunotherapy: experimental and clinical trials of its use in treatment of leukemia minimal and or residual disease. Mathé G; Weiner R; Pouillart P; Schwarzenberg L; Jasmin C; Schneider M; Hayat M; Amiel JL; de Vassal F; Rosenfeld C Natl Cancer Inst Monogr; 1973 Dec; 39():165-75. PubMed ID: 4595314 [No Abstract] [Full Text] [Related]
9. Non-leukaemic AkR mice are not tolerant to cells of leukaemia induced by Gross virus. Doré JF; Ajuria E; Mathé G Rev Eur Etud Clin Biol; 1970 Jan; 15(1):81-4. PubMed ID: 5442690 [No Abstract] [Full Text] [Related]
10. Immunoadjuvant treatment of primary grafted and spontaneous AKR-leukemia. II. In vitro cytotoxicity of lymphoid cells against normal and malignant syngeneic cells and against normal allogeneic cells. Olsson L; Ebbesen P J Immunol; 1979 Mar; 122(3):781-6. PubMed ID: 376706 [No Abstract] [Full Text] [Related]
11. Effects of active specific and non-specific immunotherapy on E male G2 leukemia according to the route of administration and combination of immunological stimulants. Amiel JL; Bĕrardet M Eur J Cancer (1965); 1971 Oct; 7(5):419-23. PubMed ID: 5159873 [No Abstract] [Full Text] [Related]
12. [Effects of B.C.G. on the hepatic catalase activity in mouse. Relation between the reticuloendothelial system and the resistance against grafted AKR leukemia]. Lamensans A; Mollier MF; Laurent M Rev Fr Etud Clin Biol; 1968 Nov; 13(9):871-6. PubMed ID: 4885127 [No Abstract] [Full Text] [Related]
13. Prevention of spontaneous leukemia in AKR mice by passive immunization and type specificity of this protection. Fish DC; Gilden RV; Bare RM; Trimmer RM; Huebner RJ J Natl Cancer Inst; 1979 Apr; 62(4):943-5. PubMed ID: 219284 [TBL] [Abstract][Full Text] [Related]